Department of Pediatrics, Division of Pediatric Cardiology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
Semin Vasc Surg. 2013 Mar;26(1):48-54. doi: 10.1053/j.semvascsurg.2013.04.001.
Vascular malformations result from an arrest of development of a normal vascular structure or from abnormal growth of a vascular structure. Treatment continues to be a challenge. We sought to study the outcomes of sclerotherapy and embolization for vascular malformations. We reviewed clinical data of all patients treated with sclerotherapy or embolization for arteriovenous or venous malformations between 2006 and 2010 at Mayo Clinic. Follow-up information was obtained from clinical charts and a questionnaire sent to all patients. Overall, 60 patients (24 male and 36 female; mean age 31.7 years; range, 5.6 to 72.4 years) had 163 unique sclerotherapy or embolization procedures for lesions involving the lower extremity (55%), upper extremity (18.3%), pelvis (11.7%), abdomen (5%), chest (5%), back (3.3%), and multiple locations (1.7%). Thirty-one patients had low-flow venous malformations and 29 patients had high-flow arteriovenous malformations. Twenty-four patients required more than three sessions. The most common indication for intervention was pain (57 of 60 [95%]). Sixteen patients (27%) had documented or patient-reported complications. There was no significant difference in complication rates or lesion size between patients with low-flow or high-flow lesions. There were no procedural deaths. Mean available follow-up was 2.0 ± 1.3 years (range, 0.5 to 5.0 years). Median pain scores at most recent follow-up decreased significantly (P<.001). Eighty-three percent of the responders (24 of 29) would recommend treatment to others. With appropriate patient selection, sclerotherapy and embolization can decrease the pain of patients with arteriovenous and venous malformations. Multiple interventions might be necessary. Practitioners should be aware of the potential complications and counsel their patients about these risks.
血管畸形是由于正常血管结构发育停滞或血管结构异常生长引起的。治疗仍然是一个挑战。我们旨在研究硬化治疗和栓塞治疗在动静脉或静脉畸形中的应用。我们回顾了 2006 年至 2010 年梅奥诊所接受硬化治疗或栓塞治疗的动静脉或静脉畸形患者的临床资料。通过病历和向所有患者发送的问卷获得随访信息。共有 60 例患者(24 例男性,36 例女性;平均年龄 31.7 岁;年龄范围 5.6 岁至 72.4 岁)接受了 163 次针对下肢(55%)、上肢(18.3%)、骨盆(11.7%)、腹部(5%)、胸部(5%)、背部(3.3%)和多处(1.7%)病变的独特的硬化治疗或栓塞治疗。31 例患者存在低流量静脉畸形,29 例患者存在高流量动静脉畸形。24 例患者需要进行超过 3 次治疗。干预的最常见指征是疼痛(60 例中的 57 例[95%])。16 例(27%)患者有记录或患者报告的并发症。低流量或高流量病变患者的并发症发生率或病变大小无显著差异。无手术相关死亡。平均随访时间为 2.0±1.3 年(范围,0.5 年至 5.0 年)。最近随访时,疼痛评分中位数显著降低(P<.001)。29 例患者中有 83%(24 例)的应答者会向他人推荐治疗。对于适当的患者选择,硬化治疗和栓塞治疗可以减轻动静脉和静脉畸形患者的疼痛。可能需要多次干预。临床医生应该意识到潜在的并发症,并向患者告知这些风险。